Session » Osteoarthritis – Clinical Poster II

Date: Monday, November 9, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1650

A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices

9:00AM-11:00AM: Abstract Number: 1647

An Oleuropein-based Dietary Supplement Improves Joint Function in Older People with High Knee Joint Pain

9:00AM-11:00AM: Abstract Number: 1653

Bilateral vs Unilateral Total Knee Arthroplasty: Racial Variation in Utilization and In-Hospital Major Complication Rates

9:00AM-11:00AM: Abstract Number: 1640

Clinically Important Improvement in Osteoarthritis Pain at Week 16 After Subcutaneous Administration of Tanezumab: Pooled Analysis from International Studies

9:00AM-11:00AM: Abstract Number: 1641

Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study

9:00AM-11:00AM: Abstract Number: 1648

Comparison of Methotrexate and Glucosamine in Primary Knee Osteoarthritis with Inflammation

9:00AM-11:00AM: Abstract Number: 1657

Do Comorbidities Limit Improvement in Pain and Physical Function After Total Knee Arthroplasty in Patients with Knee Osteoarthritis?

9:00AM-11:00AM: Abstract Number: 1662

Do Weight-bearing versus Non-weight-bearing Pain Reflect Different Pain Mechanisms in Knee Osteoarthritis?: The Multicenter Osteoarthritis Study

9:00AM-11:00AM: Abstract Number: 1649

Effect of Knee Aspiration and Intra-articular Corticosteroid Injection on Gait Biomechanics and Strength Impairment in Patients with Signs of Inflammation Due to Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1651

Efficacy and Safety of Multiple Intra-articular Corticosteroid Injections for Osteoarthritis – a Systematic Review and Meta-analysis of Randomised Controlled Trials and Observational Studies

9:00AM-11:00AM: Abstract Number: 1643

Evaluating Analgesic Response to Subcutaneous Tanezumab in Patients with Inadequate Treatment Response to Other Analgesics Based on Daily E-pain Diaries: A Pooled Analysis of 2 Randomized, Placebo-controlled Studies

9:00AM-11:00AM: Abstract Number: 1656

Knee OA Outcomes in Patients with Severe Obesity Following Bariatric Surgery or Total Knee Arthroplasty

9:00AM-11:00AM: Abstract Number: 1658

Mediation of the Association Between Obesity and Osteoarthritis by Blood Pressure, Arterial Stiffness, and Subclinical Atherosclerosis

9:00AM-11:00AM: Abstract Number: 1642

Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study

9:00AM-11:00AM: Abstract Number: 1655

Pain Reduction Post Total Knee Replacement in Opioid Users and Non-users

9:00AM-11:00AM: Abstract Number: 1645

Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program

9:00AM-11:00AM: Abstract Number: 1652

Progression of Knee OA with Use of Intra-articular Corticosteroids (CS) vs Hyaluronic Acid (HA)

9:00AM-11:00AM: Abstract Number: 1644

Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1660

Sleep Disturbance and Pain Severity and Multi-site Pain: A Prospective 10.7-year Follow-up Study

9:00AM-11:00AM: Abstract Number: 1659

Synergistic Effect of Quadriceps Weakness and Obesity in Women at Risk of Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1661

Systematic Review and Meta-Analysis of the Prevalence of Neuropathic-Like Pain and Pain Sensitisation in People with Knee and Hip Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1654

The Relationship Between Patient-Reported Readiness for Total Knee Arthroplasty and the Likelihood of a Good Outcome at One Year

9:00AM-11:00AM: Abstract Number: 1646

Use of Prescription Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Adults with Hip/Knee Osteoarthritis (OA) at Increased Risk for NSAID-related Adverse Events

9:00AM-11:00AM: Abstract Number: 1664

Walking Energetics, Fatigue, and Physical Activity in People with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1663

Walking for Exercise May Be Symptom and Structure Modifying for Those with Established OA and with Varus Alignment – Data from the Osteoarthritis Initiative

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].